Digoxin

CHF 115.00
In stock
CDX-D0175-G0011 gCHF 115.00
CDX-D0175-G0055 gCHF 459.00
More Information
Product Details
Synonyms 12β-Hydroxydigitoxin; NSC 95100
Product Type Chemical
Properties
Formula C41H64O14
MW 780.94
CAS 20830-75-5
Source/Host Chemicals Synthetic.
Purity Chemicals ≥95% (HPLC)
Appearance White powder.
Solubility Soluble in DMSO (100mM) or methanol.
Identity Determined by NMR.
Declaration Manufactured by Chemodex.
Other Product Data

Click here for Original Manufacturer Product Datasheet
Our product description may differ slightly from the original manufacturers product datasheet.

InChi Key LTMHDMANZUZIPE-PUGKRICDSA-N
Smiles [H][C@@]1(C[C@H](O)[C@H](O[C@@]2([H])C[C@H](O)[C@H](O[C@@]3([H])C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1)O[C@H]1CC[C@@]2(C)[C@]([H])(CC[C@]3([H])[C@]2([H])C[C@@H](O)[C@]2(C)[C@H](CC[C@]32O)C2=CC(=O)OC2)C1
Shipping and Handling
Shipping AMBIENT
Short Term Storage +4°C
Long Term Storage -20°C
Handling Advice Keep cool and dry.
Protect from light and moisture.
Use/Stability Stable for at least 2 years after receipt when stored at -20°C.
Documents
MSDS Inquire
Product Specification Sheet
Datasheet Download PDF

Cardiac glycoside from the leaves of Digitalis lanata. It is used to treat cardiac arrhythmias. It is often used as a model substrate of P-glycoprotein (Pgp) (0.01-10µM) and an inhibitor of Na+/K+-ATPase. Inhibits membrane-bound α-subunits of the Na+/K+ ATPase pump in myocytes. The primary mechanism of action involves inhibition of the Na+/K+ ATPase, mainly in the myocardium. This inhibition causes an increase in intracellular sodium levels, resulting in a reversal of the action of the sodium-calcium exchanger, which causes an increase in the intracellular calcium concentration. This leads to a decrease in heart rate and increased storage of calcium in the sarcoplasmic reticulum, causing a corresponding increase in the release of calcium during each action potential.

Product References

(1) R.G. Woolfson, et al.; Kidney Int. 46, 297 (1994) | (2) S. Reddy, et al.; Curr. Opin. Cardiol. 12, 233 (1997) | (3) K. Kjeldsen & H. Bundgaard; Ann. N Y Acad. Sci. 986, 702 (2003) | (4) M. Gheorghiade, et al.; Circulation 109, 2959 (2004) | (5) M. Ehle, et al.; Crit. Pathw. Cardiol. 10, 93 (2011) | (6) R.J. Biggar; Clin. Cancer Res. 18, 2133 (2012) | (7) A.M. Nader & D.R. Foster; J. Clin. Pharmacol. 54, 3 (2014) | (8) G.A. Ewy; Am. J. Med. 128, 1272 (2015)

© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.